Gender-specific considerations in the antiretroviral management of HIV-infected women

References

• Hader SL, Smith DK, Moore JS, Holmberg SD. HIV Infection in women in the United States – status at the millennium. J. Am. Med. Assoc. 285(9), 1186–1192 (2001).
   PubMed Web of Science ®Google Scholar
• Palella FJ, Delaney KM, Moorman A et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med.338(13), 853–860 (1998).
   PubMed Web of Science ®Google Scholar
• Poundstone KE, Chaisson RE, Moore RD. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 15(9), 1115–1123 (2001).
   PubMed Web of Science ®Google Scholar
• Friedland GH, Saltzman B, Vileno J, Freeman K, Schrager LK, Klein RS. Survival differences in patients with AIDS. J. Acquir. Immun. Def. Synd.4, 144–153 (1991).
   PubMed Web of Science ®Google Scholar
• Rothenberg R, Woelfel M, Stoneburner R, Milberg J, Parker R, Truman B. Survival with the acquired immunodeficiency syndrome. N. Engl. J. Med.317, 1297–1302 (1997).
   Google Scholar
• Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use and progression of HIV disease. N. Engl. J. Med.333(12), 751–756 (1995).
   PubMed Web of Science ®Google Scholar
• Mocroft A, Gill MJ, Davidson W, Phillips AN. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J. Acquir. Immune Def. Synd.24(5), 475–482 (2000).
   PubMed Web of Science ®Google Scholar
• Evans JS, Nims T, Cooley et al. Serum levels of virus burden in early-stage human immunodeficiency virus type 1 disease in women. J. Infect. Dis.175, 795–800 (1997).
   PubMedGoogle Scholar
• Sterling TR, Vlahov D, Atemborski J, Hoover DR, Margolick JB, Quinn TC. Initial HIV-1 RNA level and progression to AIDS in women and men. N. Engl. J. Med.334(10), 720–725 (2001).
   Google Scholar
• Garcia de la Hera M, Ferreros I, del Amo J et al. Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of intravenous drug users from 1986 to 2001. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA (2004) (Abstract 152).
   Google Scholar
• Sterling TR, Lyles CM, Vlahov D, Atemborski J, Margolick JB, Quinn TC. Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J. Infect. Dis.180, 666–672 (1999).
   PubMed Web of Science ®Google Scholar
• Junghans C, Ledergerber B, Chan P, Weber R, Egger M. Sex differences in HIV-1 viral load and progression to AIDS. Swiss HIV Cohort Study. Lancet 353, 589 (1999).
   PubMed Web of Science ®Google Scholar
• Moroni M. Sex differences in HIV-1 viral load and progression to AIDS. ICONA Study Group. Italian Cohort of HIV-1 positive individuals. Lancet 353(9152), 589–590 (1999).
   PubMedGoogle Scholar
• Moore RD, Cheever L, Keruly JC, Chaisson RD. Lack of sex difference in CD4+ to HIV-1 RNA viral load ratio. Lancet 353, 464–4 (1999).
   PubMedGoogle Scholar
• Anastos K, Gange SJ, Lau B et al. Association of race and gender with HIV-1 RNA levels and immunologic progression. J. Acquir. Immune Def. Synd.24, 218–226 (2000).
   PubMed Web of Science ®Google Scholar
• Finkel DG, John G, Holland B, Slim J, Smith SM. Women have a greater immunological response to effective virological HIV-1 therapy. AIDS 17(13), 2009–2010 (2003).
   PubMed Web of Science ®Google Scholar
• Giordano TP, Wright JA, Hasan MQ, White C, Graviss EA, Visnegarwala F. Do sex and race/ethnicity influence CD4+ cell response in patients who achieve virologic suppression during antiretroviral therapy? Clin. Infect. Dis.37, 433–437 (2003).
   PubMed Web of Science ®Google Scholar
• Moore AL, Sabin CA, Johnson MA, Phillips AN. Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. J. Acquir. Immune Def. Synd. 29, 197–202 (2002).
   PubMed Web of Science ®Google Scholar
• Ghani AC, Donnelly CA, Anderson RM. Patterns of antiretroviral use in the United States of America: analysis of three observational databases. HIV Med. 4, 24–32 (2003).
   PubMedGoogle Scholar
• Mayer KH, Hogan JW, Smith D et al. Clinical and immunologic progression in HIV-infected US women before and after the introduction of highly active antiretroviral therapy. J. Acquir. Immune Defic. Synd.33(5), 614–624 (2003).
   PubMed Web of Science ®Google Scholar
• Cole SR, Hernan MA, Robins JM et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am. J. Epidemiol. 158(7), 687–694 (2003).
   PubMed Web of Science ®Google Scholar
• Cook JA, Cohen MH, Burke J et al. Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J. Acquir. Immune Defic. Synd.30(4), 401–409 (2002).
   PubMed Web of Science ®Google Scholar
• Anastos K, Barron Y, Cohen MH et al. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann. Intern. Med. 140(4), 256–264 (2004).
   PubMed Web of Science ®Google Scholar
• Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Ann. Rev. Pharmacol.44, 499–523 (2004).
   Google Scholar
• Flexner CW. Factors associated with pharmacokinetic variability in HIV-infected patient Imed Options LLC (2004).
   Google Scholar
• LaPorte C, Burger D, Gyssens I, Sprenger H, Koopmans P. Gender differences in nevirapine pharmacokinetics, fact or fiction? Program and abstracts of the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Cannes, France (2003) (Abstract 10).
   Google Scholar
• Hitti J, Rosenkranz S, Cohn S et al. Sex and weight as covariates in the pharmacokinetics of efavirenz and nelfinavir. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA (2004) (Abstract 604).
   Google Scholar
• Brundage RC, Acosta EP, Haubrich R et al. Quantitation of sex differences and drug interactions. Pharmacologic studies of saquinavir in ACTG 359. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, USA (2002) (Abstract 779-W).
   Google Scholar
• Burger D, La Porte C, Vander Ende M, Miesen W, Koopmans P. Gender-related differences in efavirenz pharmacokinetics. Program and abstracts of the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Cannes, France 27–29 March 2003.
   Google Scholar
• Ribaudo H, Clifford D, Gulick R et al. Relationships between efavirenz pharmacokinetics, side effects, discontinuation, virologic response, and race: results from ACTG A5095/A5097. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA (2004) (Abstract 604).
   Google Scholar
• Barrett JS, Joshi AS, Chai M, Ludden TM, Fiske WD, Pieniaszek HJ. Population pharmacokinetic meta-analysis with efavirenz. Int. J. Clin. Pharmacol. Ther.40(11), 507–519 (2002).
   PubMed Web of Science ®Google Scholar
• Zhou SJ, Sheiner LB, D’Aquila RTD et al. Population pharmakocinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. Antimicrobial Agents Chemo.43(1), 121–128 (1999).
   PubMed Web of Science ®Google Scholar
• Candaro JA, Morse GD, Baros L et al. Zidovudine pharmacokinetics in HIV-positive women during different phases of the menstrual cycle Pharmacotherapy 13(4), 369–377 (1993).
   PubMedGoogle Scholar
• O’Brien M, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J. Acquir. Immune Defic. Synd.34(4) 407–14 (2003).
   PubMed Web of Science ®Google Scholar
• Chen RY, Westfall AO, Mugavero MJ et al. Duration of highly active antiretroviral therapy regimens. Clin. Infect. Dis. 37, 714–722 (2003).
   PubMed Web of Science ®Google Scholar
• Abel E, Painter L. Factors that influence adherence to HIV medications: perceptions of women and health care providers. J. Assoc. Nurses AIDS Care14, 61–69 (2003).
   PubMedGoogle Scholar
• Silverberg MJ, Gore ME, French AL et al. Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the women’s Interagency HIV Study. Clin. Infect. Dis.39, 717–724 (2004).
   PubMed Web of Science ®Google Scholar
• Ofotokun I, Pomeroy C. Sex differences in adverse reactions to antiretroviral drugs. Top. HIV Med. 11(2), 55–59 (2003).
   Google Scholar
• Cotton DJ, Finkelstein DM, He W, Feinberg J. Determinants of accrual of women to a large, multicenter clinical trials program of human immunodeficiency virus infection. The AIDS Clinical Trials Group. J. Acquir. Immune Defic. Synd.6, 1322–1328 (1993).
   PubMed Web of Science ®Google Scholar
• Squires K, Gulick R, Pavia A et al. Sex differences in the selection of thymidine analog regimen therapy trials (START II and START II). 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA (2000) (Abstract 516).
   Google Scholar
• Currier J, Spino C, Grimes J. Differences between women and men in adverse events and CD4+ responses to nucleoside analog therapy for HIV infection. J. Acquir. Immune Def. Synd. 24(4), 316–324 (2000).
   PubMed Web of Science ®Google Scholar
• Moore RD, Fortgang I, Keruly J, Chaisson RE. Adverse events from drug therapy for human immunodeficiency virus disease. Am. J. Med. 101, 34–40 (1996).
   PubMed Web of Science ®Google Scholar
• Boxwell DE, Styrt BA. Lactic acidosis in patients receiving nucleoside reverse transcriptase inhibitors. 39th Interscience Conference on Antimicrob. Agents Chemother. San Francisco, CA, USA (1999) (Abstract 1284).
   Google Scholar
• Mazhude C, Jones S, Taylor C. Ethnic and gender differences in non-nucleoside reverse transcriptase inhibitor (NNRTI) induces rash. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina (2001) (Abstract 526).
   Google Scholar
• Bersoff-Matcha SJ, Miller WC, Aberg JA et al. Sex difference in nevirapine rash. Clin. Infect. Dis.32, 124–129 (2001).
   PubMed Web of Science ®Google Scholar
• Wong KH, Chan KC, Lee SS. Sex differences in nevirapine rash. Clin. Infect. Dis.33, 2096–2098 (2001).
   PubMedGoogle Scholar
• Antinori A, Baldini F, Girardi E et al. Female sex and the use of anti-allergic agents increase the risk of developing coetaneous rash associated with nevirapine therapy. AIDS 15(12), 1579–1581 (2001).
   PubMed Web of Science ®Google Scholar
• Barlett J. Severe liver toxicity in patients receiving two nucleoside analogs and a non-nucleoside reverse transcriptase inhibitor. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA (2001) (Abstract 19).
   Google Scholar
• Sanne I. Severe liver toxicity in patients receiving two nucleoside analogs and a non-nucleoside reverse transcriptase inhibitor. AIDS 14(Suppl. 4), S12 (2000).
   Google Scholar
• Currier JS, Yetzer E, Potthoff A et al. Gender differences in adverse events on ritonavir. An analysis from Abbott 247. 1st National Conference on Women and HIV. Pasadena, CA, USA (1997) (Abstract 304.7).
   Google Scholar
• Gatti G, Di Biagnio A, Beltrame A et al. Gender as a risk factor for ritonavir intolerance. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA (1999) (Abstract 2210).
   Google Scholar
• Gersten M, Chapman S, Farnsworth A et al. The safety and efficacy of Viracept (nelfinavir mesylate) in female patients who participated in pivotal II/III double blind randomized controlled trials. 1st National Conference on Women and HIV. Pasadena, CA, USA (1997) (Abstract 304.1).
   Google Scholar
• Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J. Infect. Dis.186, 23–31 (2002).
   PubMed Web of Science ®Google Scholar
• Nguyen ML, Nagy GS, Hernandez I et al. Use of HAART in women: similar response but greater toxicity. 14th International AIDS Conference. Boston, MA, USA (2003) (Abstract WePeB5968).
   Google Scholar
• Jacobson DL, Knox T, Gorback S, Wanke C. Evolution of fat atrophy (FA) and fat deposition (FD) over 1 year in a cohort of HIV-infected men and women. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA (2002) (Abstract 685T).
   Google Scholar
• Koko-Ekong S, Azubike U, Edong E, Uwah A, Akinlade O. Fat redistribution in HIV patients on non-protease inhibitor (PI) Regimens–Study in 6 Centers in Nigeria. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA (2002) (Abstract 684T).
   Google Scholar
• McDermott AY, Shevitz A, Knox T, Roubenoff R, Kehayias J, Gorbach S. Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am. J. Clin. Nutr.74, 679–686 (2001).
   PubMed Web of Science ®Google Scholar
• Galli M, Veglia F, Angarano G et al. Risk of developing metabolic and morphological alterations under antiretroviral therapy according to drug combinations. Antivir. Ther.5(Suppl 5), 59–60 (2000) (Abstract P61).
   Google Scholar
• Thiebaut R, Daucourt V, Mercei P et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine cohort, France, 1999. Clin. Infect. Dis.31,1482–1487 (2000).
   PubMed Web of Science ®Google Scholar
• Martinez E, Mocroft A, Garcia-Viejo M et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 357, 592–598 (2001).
   PubMed Web of Science ®Google Scholar
• Falutz J, Murrahainen N, Workman C et al. Gender is associated with increased body size but not fat depletion in patients with HIV-associated adipose redistribution (HARS). Programs and Abstracts of the 13th International AIDS Conference. Durban, South Africa (2000) (Abstract WePeB4273).
   Google Scholar
• Lichenstien K, Delaney K, Ward D, Patella F. Clinical factors associated with incidence and prevalence of fat atrophy and accumulation. Antivir. Ther.5(Suppl. 5), 61–62 (2000) (Abstract P64).
   Google Scholar
• Clark RA, Theall K, Abernathy R, Arora A. Antiretroviral class effect on risk for selected metabolic complications. Infectious Diseases Society of America Meeting, Boston MA (2004) (Abstract 931).
   Google Scholar
• Pernerstorfer-Schoen H, Jilma B, Perschler A et al. Sex differences in HAART-associated dyslipidaemia. AIDS 15, 725–734 (2001).
   PubMed Web of Science ®Google Scholar
• Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J. Clin. Endocrinol. Metab. 84(6), 1932–1937 (1999).
   PubMed Web of Science ®Google Scholar
• Dong KL, Bausserman LL, Flynn MM et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART) J. Acquir. Immune Defic.21(2), 107–113 (1999).
   PubMed Web of Science ®Google Scholar
• Gervasoni C, Ridolfo AL, Trifiro G et al. Redistribution of body fat in HIV-infected women undergoing combination antiretroviral therapy. AIDS 13(4), 465–471 (1999).
   PubMed Web of Science ®Google Scholar
• Tien PC, Cole SR, Williams CM et al. Incidence of lipoatrophy and lipohypertrophy in the Women’s Interagency HIV Study. 10th Conference on Retroviruses and Opportunistic Infections. Boston. MA, USA (2003) (Abstract 736).
   Google Scholar
• Howard AA, Freeman R, Santoro N, Schoenbaum EE. Body composition and antiretroviral use in older HIV-infected women. 10th Conference on Retroviruses and Opportunistic Infections. Boston MA, USA (2003) (Abstract 735).
   Google Scholar
• Justman JE, Benning L, Danoff A et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J. Acquir. Immune Defic. Synd.32(3), 298–302 (2003).
   PubMed Web of Science ®Google Scholar
• Arnsten JH, Freeman R, Santoro N, Kunins H, Schoenbaum EE. Bone mineral density and protease inhibitor use in older HIV-infected women. 9th Conference on Retroviruses and Opportunistic Infections. Seattle WA, USA (2002) (Abstract 717-T).
   Google Scholar
• Anastos K, Hessol N, Lincoln et al. The association of bone mineral density with HIV infection and antiretroviral treatment in women. 11th Conference on Retroviruses and Opportunistic infections. San Francisco, CA, USA (2004) (Abstract 744).
   Google Scholar
• Jacobson D, Knox T, Shevitz A, Gorbach S. Low bone mineral density in HIV-infected women. 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA (2003) (Abstract 102).
   Google Scholar
• Arnsten JH, Freeman R, Santoro N, Schoenbaum EE. HIV infection and protease inhibitor use are not associated with reduced bone mineral density in older HIV-infected women. 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA (2003) (Abstract 103).
   Google Scholar
• Clark RA, Theall K. Population-based study evaluating association between selected antiretroviral therapies and potential oral contraceptive pill failure J. Acquir. Immune Def. Synd.(2004) (In Press).
   Google Scholar
• Frohlich M, Burhenne J, Martin-Facklam M et al. Oral contraception does not alter single dose saquinavir pharmacokinetics in women. Brit. J. Clin. Pharmacol.57(3), 244–252 (2004).
   PubMed Web of Science ®Google Scholar
• Cejtin HE, Jacobson L, Springer G et al. Effect of hormonal contraceptive use on plasma HIV-1-RNA levels among HIV-infected women. AIDS 17(11), 1702–1704 (2003).
   PubMedGoogle Scholar
• Watts DH. Drug therapy: management of human immunodeficiency virus infection in pregnancy. N. Engl. J. Med.346(24), 1879–1891 (2002).
   PubMed Web of Science ®Google Scholar
• Baylor M, Truffa M, Gibbs N. Hepatic toxicity of antiretrovirals in HIV-infected pregnant women: the FDA’s adverse-event reporting system. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA (2004) (Abstract 944).
   Google Scholar
• Ibdah JA, Yang Z, Bennett MJ. Liver disease in pregnancy and fetal fatty acid oxidation defects. Mol. Genet. Metab. 71, 182–189 (2000).
   PubMed Web of Science ®Google Scholar
• Blanche S, Tardieu M, Rustin P et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 354, 1084–1089 (1999).
   PubMed Web of Science ®Google Scholar
• The Perinatal Safety Review Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J. Acquir. Immune Defic. Synd. Hum. Retrovirol. 25, 261–268 (2000).
   Google Scholar
• Stek A, Khoury M, Kramer F, Homans J, Rogher C, Kovacs A. Maternal and infant outcomes with highly active antiretroviral therapy during pregnancy. 6th Retrovirus Conference. Chicago, IL, USA (1999) (Abstract 683).
   Google Scholar
• Joao E, Calvet GA, Menezes JA. Evaluation of nevirapine toxicity in a cohort of pregnant women. 15th International AIDS Conference, Bangkok. Thailand (2004) (Abstract ThOrB1354).
   Google Scholar
• Gonzalez-Garcia A, Fernandez MI, Cotter A. Nevirapine toxicity in the obstetric population when used in combination with other ARV. 15th International AIDS Conference. Bangkok, Thailand (2004) (Abstract WePeB5918).
   Google Scholar
• Kramer F, Stek A, Du WB, Kovacs A. Nevirapine tolerability in HIV infected women in pregnancy. 11th Retrovirus Conference. San Francisco, CA, USA (2004) (Abstract 923).
   Google Scholar
• Hitti J, Frenkel L, Huang S et al. Toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. 11th Conference on Retroviruses and Opportunistic Infections San Francisco. CA, USA (2004) (Abstract 938).
   Google Scholar
• Scarsi KK, Postelnick MJ. The impact of gender and pregnancy on antiretroviral therapy for HIV: pharmacokinetic and disease-related differences. J. Gend. Specif. Med. 6(1), 7–16 (2003).
   PubMedGoogle Scholar
• Dorenbaum A, Cunningham CK, Gelber RD et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV-1 transmission: a randomized trial. J. Am. Med. Assoc. 288, 189–98 (2002).
   PubMed Web of Science ®Google Scholar
• Kosel BW, Beckerman KP, Hayashi S, Homma M, Aweeka FT. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS 17(8), 1195–1199 (2003).
   PubMed Web of Science ®Google Scholar
• Nellen JFJB, Schillevoort I, Wit FWNM et al. Nelfinavir plasma concentrations are low during pregnancy. Clin. Infect. Dis.39, 736–740 (2004).
   PubMed Web of Science ®Google Scholar
• Bryson Y, Stek A, Mirochnik M et al. A phase I study of safety, pharmacokinetics and antiviral activity of combination nelfinavir, ZDV and 3TC in HIV-infected pregnant women and their infants. 7th Retrovirus Conference. San Francisco, CA, USA (2002) (Poster presentation 715).
   Google Scholar
• Bryson Y, Stek A, Mirochnik et al. Pharmacokinetics (PK), antiviral activity and safety of nelfinavir (NFV) with ZDV/3TC in pregnant HIV-infected women and their infants: PACTG 353 Cohort 2. 9th Retrovirus Conference. Seattle. WA, USA (2002) (Poster presentation 795-W).
   Google Scholar
• Acosta EP, Bardeguez A, Zorrilla CD et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob. Agents Chemother. 48(2), 430–436 (2004).
   PubMed Web of Science ®Google Scholar
• Lopez-Cortes LF, Ruiz-Valderas R, Pascual R et al. Once-daily saquinavir-hgc plus low-dose ritonavir (1200/100 mg) in HIV-infected pregnant women: pharmacokinetics and efficacy. HIV Clin. Trials4(3), 227–229 (2003).
   PubMed Web of Science ®Google Scholar
• Stek A, Mirochnick, Capparelli E et al. Reduced lopinavir exposure during pregnancy: preliminary pharmacokinetic results from PACTG 1026. XVth International AIDS Conference. Bangkok, Thailand July 11–16 (2004) (Abstract Lb0rB08).
   Google Scholar
• Guay LA, Muoke P, Fleming T et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 trial. Lancet 354, 795–802 (1999).
   PubMed Web of Science ®Google Scholar
• Coovadia H. Antiretroviral agents – how best to protect infants from HIV and save their mothers from AIDS. N. Engl. J. Med. 351(3), 289–290 (2004).
   PubMed Web of Science ®Google Scholar
• Taha TE, Kumwenda NI, Hoover DR et al. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting. J. Am. Med. Assoc. 292, 202–209 (2004).
   PubMed Web of Science ®Google Scholar
• Lallemant M, Jourdain G, Le Coeur S et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N. Engl. J. Med.351(3), 217–228 (2004).
   PubMed Web of Science ®Google Scholar
• Eastman PS, Shapiro DE, Coombs RW et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in Pediatric AIDS Clinical Trials Group Protocol 076. J. Infect. Dis.177(3), 557–564 (1998).
   PubMed Web of Science ®Google Scholar
• Mofenson L, Lmabert J, Stiehm et al. Association of ZDV genotypic resistance with perinatal HIV transmission in women receiving ZDV in pediatric AIDS Clinical Trials Group (PACTG) Protocol 185. XIII International AIDS Conference. Durban, South Africa (2000) (Abstract TuPpB1229).
   Google Scholar
• Nolan M, Fowler MG, Mofenson LM. Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance. J. Acquir. Immune Def. Synd.30, 216–229 (2002).
   PubMedGoogle Scholar
• Welles SL, Pitt J, Colgrove R et al. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the Women and Infants Transmission Study Group. AIDS. 14(3) 263–271 (2000).
   PubMedGoogle Scholar
• Palumbo P, Holland B, Dobbs T et al. Antiretroviral resistance mutations among pregnant HIV-1-infected women and their newborns in the US: Vertical transmission and clades. J. Infect. Dis.184(11), 1120–1126 (2001).
   PubMed Web of Science ®Google Scholar
• Kully C, Yerly S, Erb P et al. Codon 215 mutations in human immunodeficiency virus-infected pregnant women. J. Infect. Dis. 179(3), 705–708 (1999).
   PubMed Web of Science ®Google Scholar
• Mandelbrot L, Landreau-Mascaro A, Rekacewicz C et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. J. Am. Med. Assoc. 285(16), 2083–2093 (2001).
   PubMed Web of Science ®Google Scholar
• Cunningham CK, Britto P, Gelber R et al.: Genotypic resistance analysis in women participating in PACTG 316 with HIV-1 RNA > 400 copies/ml. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, USA (2001) (Abstract 712).
   Google Scholar
• Guiliano M, Palmisano L, Galluzzo CM et al. Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission. AIDS 17(10), 1570–1572 (2003).
   PubMedGoogle Scholar
• Eshleman SJ, Becker-Pergola G, Deseyve M et al. Impact of human immunodeficiency virus type 1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV-1 vertical transmission (HIV Network for Prevention Trials 012 Study). J. Infect. Dis.184(10), 914–917 (2001).
   PubMed Web of Science ®Google Scholar
• Eshleman SH, Mracna M, Guay LA et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 15(15), 1951–1957 (2001).
   PubMed Web of Science ®Google Scholar
• Lallemant M, Jourdain G, LeCoeur S et al. A randomized, double-blind trial assessing the efficacy of single dose nevirapine added to a standard zidovudine regimen for the prevention of mother-to-child transmission of HIV-1 in Thailand. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA (2004) (Abstract 40 LB).
   Google Scholar
• Jourdain G, Ngo-Giang-Huong N, Tungyai P et al. Exposure to intrapartum single-dose nevirapine and subsequent maternal 6-month response to NNRTI regimens. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA (2004) (Abstract 41 LB).
   Google Scholar
• Martinson N, Morris L, Gray G et al. HIV resistance and transmission following single-dose nevirapine in a PMTCT cohort. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA (2004) (Abstract 38).
   Google Scholar
• Antinori A, Zaccarelli M, Cingolani A et al. Cross-resistance among nonnucleoside reverse trascriptase inhibitors limits recycling efavirenz after NVP failure. AIDS Res. Hum. Retroviruses 18, 838–8 (2002).
   Google Scholar
• Jourain G, Ngo-Giang-Huong N, Le Coeur S et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N. Engl. J. Med.351(3), 229–240 (2004).
   PubMedGoogle Scholar
• Burke JK, Cook JA, Cohen MH et al. Dissatisfaction with medical care among women with HIV: dimensions and associated factors AIDS Care 15(4), 451–462 (2003).
   PubMed Web of Science ®Google Scholar